尿路感染症に対するAM-715の基礎的・臨床的検討 (AM-715<特集>)
スポンサーリンク
概要
- 論文の詳細を見る
AM-715, a new quinolinecarboxylic acid derivative was evaluated both bacteriologically and clinically on urinary tract infections, and following conclusions were obtained.<BR>1. In the standard strains, both gram-negative and gram-positive bacteria were susceptible to AM-715. The concentrations required to inhibit the growth of 90% of the clinical isolates of <I>E. coli</I> (93 strains), <I>P. aeruginosa</I> (55 strains) and <I>Serratia</I> spp.(26 strains) were 0.20μg/ ml, 12.5μg/ ml and 6.25μg/ ml, respectively.<BR>2. The peak of urinary concentrations after oral administration of 400mg, 200mg and 100mg of AM-715 were 372mu;g/ ml at 0-2 hour, 133μg/ ml at 2-4 hour, and 77.8μg/ ml at 0-2 hour, respectively. Recoveries within 12 hours were 25.5% 18.7%, and 26.5%, respectively.<BR>3. All of 36 patients with acute simple cystitis responded to AM-715 therapy (400 mg/ day). Efficacy on pyuria was found to be 92% in respect to "cleared" response, efficacy on bacteriuria to be 97% in respect to "eliminated" response and efficacy on pain on urination to be 100% in respect to "resolved" and "improved" responses.<BR>4. Overall clinical efficacy of 67 cases with complicated urinary tract infections treated with AM-715 (800mg/ day, p. o.) was found to be 85 % in respect to both "excellent" and "moderate" responses. The rate of efficacy on pyuria was found to be 63 % in "cleared" response, 15 % in "decreased" response and 22% in "unchanged". The rate of efficacy on bacteriuria was found to be 81% in "eliminated", 4% in "replaced" and 15% in "unchanged".<BR>5. In 83 urinary isolates from 67 cases with complicated urinary tract infections the elimination rate was 88%. The elimination rate of gram-positive cocci was 87%.<BR>6. Incidence of side effect was 4.2%(5/ 119). All of these side effects may be attributable to administration of AM-715. Deterioration in laboratory test results was found in 8 of 26 cases, probably not attributable to drug.<BR>In conclusions, AM-715 is suggested to be a useful and safe drug for urinary tract infections.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.